Healthcare Unfiltered Episode 270: Translational Research Questions in Small Cell Lung Cancer
11 snips
Mar 10, 2026 Misty Shields, physician-scientist and thoracic oncologist at Indiana University who studies small cell lung cancer, discusses shifting biological classifications, evolving roles for prophylactic cranial radiation and immunotherapy, and translational work on biomarkers, liquid biopsies, and novel targets. Short sentences highlight funding hurdles, lab–clinic integration, and optimism for near-term therapeutic progress.
AI Snips
Chapters
Books
Transcript
Episode notes
Personal Journey Into Small Cell Research
- Misty Shields chose small cell lung cancer because her father died of the disease when she was in eighth grade and she watched his treatment at the Dallas VA.
- That personal loss motivated her to train with mentors like John Minna and build a career focused on small cell translational research.
Small Cell Has Distinct Molecular Subtypes
- Small cell is not homogeneous — molecular subtypes (ASCL1, NEUROD1, POU2F3, inflamed) reveal distinct biology and therapy opportunities.
- Subtype discovery enabled DLL3 targeting and paved the way for effective agents like tarlatamab in selected patients.
Treating Limited Stage With ChemoRT Then Immunotherapy
- For limited stage small cell, deliver concurrent chemo and radiation with curative intent then offer adjuvant immunotherapy (durvalumab) for up to two years if no progression.
- Explain risks and shared decision-making for prophylactic cranial irradiation versus MRI surveillance.
